Evaluation of histopathological criteria for identifying nodenegative breast cancer with high risk of early recurrence in the NSAS-BC protocol study

Breast Cancer

Volumn 7, Issue 3, 2000, Pages 201-209

  Tsuda, Hitoshi ^a,b   Takarabe, Teruko ^a   Akashi Tanaka, Sadako ^a   Fukutomi, Takashi ^a   Nanasawa, Takeshi ^a   Watanabe, Toru ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Invasion; Node negative breast cancer; Nuclear grand; Prognostic factor; Protocol study

Indexed keywords

ADULT; AGED; ARTICLE; BIOPSY; BREAST TUMOR; CANCER STAGING; CLINICAL PROTOCOL; FEMALE; HUMAN; JAPAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MASTECTOMY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; STANDARD; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BREAST NEOPLASMS; CLINICAL PROTOCOLS; FEMALE; HUMANS; JAPAN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MASTECTOMY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034565607     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967461     Document Type: Article

References (19)

1. Watanabe T: Protocol for clinical trials (1). Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur) versus six-cycle CMF (cyclophosphamide/methotrexate/ 5-fluorouracil) in high-risk node-negative breast cancer patients. Jpn J Clin Oncol 28:77-80, 1998. (Pubitemid 128527487)
2. Tsuda H, Akiyama F, Kurosumi M, et al: Establishment of histological criteria for high-risk nodenegative breast carcinoma in a randomized clinical trial of adjuvant therapy. Jpn J Clin Oncol 28:486-491, 1998. (Pubitemid 128527326)
3. Tsuda H, Akiyama F, Kurosumi M, et al: The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. Jpn J Clin Oncol 29: 68-73, 1999.
4. Tsuda H, Akiyama F, Kurosumi M, et al: Quality management of individual pathologists' judgments of nuclear atypia of breast cancer by slide conferences in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Clin Oncol 29:413-420, 1999.
5. Donegan WL, Spratt JS: Cancer of the Breast. 4th Ed, WB Saunders Co., Philadelphia, pp 652-665, 1995.
6. Tsuda H, Hirohashi S: Identification of multiple breast cancers of multicentric origin by histological observations and distribution of allele loss on chromosome 16q. Cancer Res 55:3395-3398, 1995.
7. Koyama T, Hasebe T, Tsuda H, et al: Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast. Jpn J Cancer Res 90:294-300, 1999. (Pubitemid 29164019)
8. Tsuda H, Takarabe T, Hasegawa F, et al: Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197-202, 2000. (Pubitemid 30078708)
9. Tsuda H, Sakamaki C, Fukutomi T, et al: Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis, and recurrence sites. Br J Cancer 75:1519-1524, 1997. (Pubitemid 27196876)
10. Fisher ER, Gregorio RM, Redmond C, et al: Tubolobular invasive breast cancer: A variant of lobular invasive cancer. Hum Pathol 8: 679-683, 1977. (Pubitemid 8235756)
11. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957.
12. Contesso G, Mouriesse, H, Friedman S, et al: The importance of histologic grade in long-term prognosis of breast cancer: A study of 1, 010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oneol 5: 1378-1386, 1987.
13. Elston CW: Grading of invasive carcinoma of the breast. In: Page DL, Anderson TV eds., Diagnostic Histopathology of the Breast, Churchill Livingstone, New York, pp300-311, 1987.
14. Page DL, Ellis IO, Elston CW: Histologic grading of breast cancer. Let's do it. Am J Clin Pathol 103:123-124, 1995.
15. Pharoah PD, Day NE, Caldas C: Somatic mutations in the p53 gene and prognosis in breast cancer: A metaanalysis. Br J Cancer 80:1968-1973, 1999. (Pubitemid 29391282)
16. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992.
17. Iwaya K, Tsuda H, Fukutomi T, et al: Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 27:6-12, 1997. (Pubitemid 127516277)
18. Saimura M, Fukutomi T, Tsuda H, et al: Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: Analysis of clinicopathological prognostic factors. J Surg Oncol 71:101-105, 1999. (Pubitemid 29288487)
19. Tsuda H, Takarabe T, Fukutomi T, et al: Preferential occurrence of breast carcinomas with loss of chromosome 16q and der(16)t(1;16)/der(1;16) formation in middle-aged patients with hyperplasia of mammary glands. Jpn J Cancer Res 91:692-699, 2000. (Pubitemid 30612353)